RxDoctor Payments Data

Maris McIntyre, DO

Family Medicine · Westmont, ILNPI 1063652204

Payments from drug & device makers

$4,785in general payments, 2019–2025

Across 268 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$756
  • Amarin Pharma, Inc.$642
  • Amgen$437
  • Lilly USA, LLC$384
  • Johnson & Johnson$251
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,779100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,785 in reported general payments places this provider in the 90th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$43,304
Medicare patients
90
Services billed
525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol34$42,790
MounjaroTirzepatide17$29,671
OzempicSemaglutide16$20,665
VascepaIcosapent Ethyl13$11,506
Atorvastatin Calcium116$935
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$711
Levothyroxine Sodium69$703
Albuterol Sulfate HfaAlbuterol Sulfate15$576
Fenofibrate15$540
Fluticasone Propionate26$534
Tamsulosin Hcl27$481
Metoprolol Succinate40$474
Rosuvastatin Calcium57$457
Amlodipine Besylate62$428
Lisinopril47$425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$756$42,79034 claims
Lilly USA, LLCMounjaro$384$29,67117 claims
Novo NordiskOzempic$131$20,66516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Westmont

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →